Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.
Journal: Leukemia & lymphoma
Published: April 29, 2026
Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.
Journal: bioRxiv : the preprint server for biology
Published: February 27, 2026
Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma.
Journal: Advances in therapy
Published: December 19, 2025
AI for evidence-based treatment recommendation in oncology: a blinded evaluation of large language models and agentic workflows.
Journal: Frontiers in artificial intelligence
Published: August 10, 2025
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.
Journal: Lancet (London, England)
Published: July 15, 2025
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.
Journal: medRxiv : the preprint server for health sciences
Published: March 10, 2025
Whole-Blood Longitudinal Molecular Profiling Maps the Road of Graft Versus Host Disease (GVHD).
Journal: Cancers
Published: January 15, 2025
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.
Journal: medRxiv : the preprint server for health sciences
Published: January 07, 2025
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma.
Journal: Transplantation and cellular therapy
Published: December 26, 2024
Last Updated: 09/26/2026